First FDA-approved liquid botulinum toxin type A formulation (Hall strain) with 50 units/vial in buffered saline (pH 7.0). Features 90% neurotoxin purity and 10-month duration in clinical trials. Contains zero animal proteins (L-methionine stabilized) for reduced immunogenicity (0.3% adverse reaction rate).

Advanced Stabilization: Utilizes polysorbate 20 (0.05% w/v) and L-methionine (0.5mg/ml) for protein protection without albumin. Maintains 4.8-7.2 pH range through phosphate buffer system.

🧪 Sterile single-use vial
📦 2.5ml solution (50U±5%)
📅 24-month refrigerated stability (2-8°C)

Clinical Protocol:
1. Reconstitution not required
2. Administer within 4hrs after opening
3. Standard dosing: 4U per injection site (glabella)
4. Max 50U per session (FDA guidelines)
5. Use 30G-32G needles for precision

⚠ Prescription medication. For licensed practitioners only. Contraindicated in pregnancy (Category C) and neuromuscular disorders. Adverse effects may include ptosis (2.1%), headache (1.3%), injection site pain (0.9%). MD approval required.Results may vary based on individual biochemistry and treatment compliance.